Morepen Laboratories Q4 FY26 profit up 69% to ₹20 crore

Overview: Q4 print highlights and what changed

Morepen Laboratories Limited reported a stronger Q4 FY26 performance on the back of export momentum and growth in its Medical Devices business. The company said Q4 FY26 gross revenue rose 22% year-on-year to ₹472 crore, while net profit increased 69% to ₹20 crore for the quarter. It also pointed to improving operational momentum toward the latter part of FY26, helped by the start of commercial production under a long-duration manufacturing partnership programme. Alongside quarterly performance, investors also tracked updates on the company’s multi-year CDMO mandate and capacity expansion plans. Separately, Morepen’s consolidated numbers for Q4 and FY26 showed pressure on profitability even as revenue moved up modestly. The board proposed a final dividend of ₹0.20 per equity share for FY26, subject to shareholder approval.

Q4 FY26: revenue rose, profit picture differs across disclosures

In its Q4 FY26 update, the company reported gross revenue of ₹472 crore, up 22% year-on-year. It also reported net profit of ₹20 crore for the quarter, up 69% year-on-year, and linked the improvement to exports, medical devices expansion, and CDMO-related production commencement. However, consolidated disclosures cited a different profitability trend for the same quarter. Morepen reported Q4 consolidated net profit of ₹15.7 crore (₹157 million), down from ₹20.3 crore (₹203 million) year-on-year. Consolidated revenue for the quarter was reported at about ₹484 crore (₹4.84 billion), up from about ₹470 crore (₹4.7 billion) year-on-year.

BSE consolidated quarterly data for March 2026 also showed total revenue of ₹493.18 crore, operating profit of ₹24.45 crore, and net profit of ₹15.74 crore. The same table showed operating profit down 42.1% year-on-year and net profit down 22.5% year-on-year, along with a decline in adjusted EPS to 0.29 for the latest quarter.

EBITDA and margins: investments weighed on operating profitability

Morepen reported Q4 FY26 EBITDA of ₹32 crore versus ₹33 crore in Q4 FY25, and said the movement reflected continued investments in manufacturing scale-up, regulated-market programmes, and expansion in medical devices. In the consolidated metric set included in the article, Q4 EBITDA fell to ₹24.4 crore (₹244 million) from ₹42.3 crore (₹423 million) year-on-year. The Q4 EBITDA margin was reported at 5.04%, down from 9.1% in the year-ago period. These figures indicate that while the top line improved, operating profitability faced pressure during the quarter.

CDMO mandate: commercial production begins, deliveries expected in phases

A key operational update in Q4 FY26 was the commencement of commercial production linked to a multi-year global CDMO mandate valued at ₹825 crore. The company said validation batches have been completed. It added that phased deliveries are expected to begin shortly. In an earlier disclosure referenced in the article, Morepen said supplies under the mandate were expected to commence within the next four to five months, with execution scheduled through Q1 FY27, subject to customary operational and regulatory processes. Morepen did not name the global pharma counterparty in the disclosures referenced.

Capacity expansion: moving from nearly 500 KL to 800 KL

Morepen said manufacturing capacity expansion is underway from nearly 500 KL to 800 KL. The company linked its investment cycle to manufacturing scale-up and regulated-market programmes. While it did not provide a timeline in the provided text, the capacity expansion is positioned as part of readiness to support growth initiatives, including longer-duration manufacturing partnerships.

Medical Devices business: FY26 growth and user base update

For FY26, the company said the Medical Devices business reported 21% annual revenue growth to ₹598 crore. It also stated that the business reached an installed base of nearly 17 million repeat users. In the Q4 narrative, Morepen highlighted the expansion of the Medical Devices business as one of the drivers of quarterly momentum.

FY26 performance: standalone revenue above ₹1,700 crore; consolidated profit lower

For FY26, Morepen said standalone gross revenue crossed ₹1,700 crore, up 8% from the previous year. In the consolidated financial comparison included in the article, full-year consolidated net profit declined to ₹95.65 crore (₹9,564.65 lakh) from ₹118.02 crore (₹11,801.54 lakh) in FY25. Consolidated total income for FY26 was ₹1,827.01 crore (₹182,700.56 lakh), slightly lower than ₹1,829.94 crore (₹182,993.95 lakh) in FY25.

On a standalone basis for the year, net profit was ₹66.06 crore (₹6,605.75 lakh), down from ₹101.58 crore (₹10,157.52 lakh) in the corresponding period. Standalone total income rose to ₹1,702.69 crore (₹170,269.01 lakh) from ₹1,570.25 crore (₹157,025.49 lakh).

Dividend and corporate action: ₹0.20 per share recommended

The Board of Directors, in a meeting held on May 26, 2026, recommended a final dividend of ₹0.20 per equity share (face value ₹2 each) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. The company also described this as a 10% dividend for FY26.

Subsidiary stake change: Morepen Medipath share transfer

Morepen Laboratories transferred 1,62,000 equity shares of its subsidiary Morepen Medipath Limited (MML) to Mr. Anubhav Suri, Head - Medical Devices Business. Following the transfer, Morepen’s stake in MML reduced from 60% to 51%. The company said MML will continue to remain a subsidiary and will be consolidated in its financial statements. Mr. Suri’s shareholding increased from 0.10% to 9.10%.

Key numbers at a glance

Market impact: stock reaction seen around CDMO announcement

The article also referenced market moves around the CDMO mandate announcement. Morepen Laboratories’ shares were reported trading 18% higher at ₹46.45 on the BSE at 2:36 pm on the day of the contract disclosure. Another market update cited the stock up 13.38% to ₹44.57 after the CDMO mandate announcement.

Why the updates matter: growth drivers versus margin pressure

The quarter combined multiple cross-currents that matter to investors tracking the healthcare and pharmaceuticals space. On one hand, the company reported strong year-on-year growth in gross revenue and net profit in its Q4 FY26 narrative, and it highlighted exports and medical devices as key drivers. It also confirmed that commercial production has started under a multi-year CDMO mandate, with validation batches completed and phased deliveries expected to start shortly. On the other hand, the consolidated metrics cited in the same text showed year-on-year declines in quarterly net profit and EBITDA, and a sharp contraction in EBITDA margin.

The FY26 picture also diverges by lens. Standalone gross revenue crossed ₹1,700 crore with year-on-year growth, while consolidated net profit for the full year declined versus FY25 despite broadly stable total income. The dividend recommendation of ₹0.20 per share provides a defined shareholder payout proposal that will be subject to approval at the AGM.

Conclusion: focus on execution, deliveries, and cost discipline

Morepen’s Q4 FY26 announcements bring together three themes: growth in exports and medical devices, the operational start of a large CDMO engagement, and an ongoing capacity expansion from nearly 500 KL to 800 KL. At the same time, consolidated profitability indicators in the article point to margin pressure during the quarter. The next set of milestones in the company’s own disclosures is the start of phased deliveries under the CDMO mandate and progress updates on the manufacturing scale-up, alongside shareholder approval for the proposed ₹0.20 final dividend.